STOCK TITAN

Bausch Health Companies (BHC) Stock News, Aug-Sep 2020

BHC NYSE

Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.

Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.

Rhea-AI Summary

Bausch Health has announced an agreement to acquire an option to purchase all ophthalmology assets from Allegro Ophthalmics, including global rights to risuteganib, an investigational treatment for dry age-related macular degeneration (AMD). The acquisition is valued at $50 million, with a $10 million initial payment and a contingent $40 million payment expected in 2021. Risuteganib targets multiple pathways involved in AMD, addressing a significant unmet medical need affecting millions globally. The acquisition aligns with Bausch Health's strategy to enhance its pipeline in eye health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.90%
Tags
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a presentation by CEO Joseph C. Papa and CFO Paul S. Herendeen at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. The presentation focuses on the company's business recovery post-COVID-19 and updates on its plan to spin off the eye health business. The presentation details are available on Bausch Health's Investor Relations page. Bausch Health aims to enhance global health through its pharmaceutical and medical products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
-
Rhea-AI Summary

The Bausch Foundation, overseen by Bausch Health (BHC), released its inaugural activity report detailing philanthropy initiatives from late 2017 to June 30, 2020. The Foundation aims to enhance patient lives globally by providing access to essential medicines and supporting healthcare education. Notably, Bausch Health donated approximately $600 million in pharmaceutical products in 2018 and 2019 to aid financially struggling patients. The Foundation focuses on disease prevention, improving patient outcomes, education, and global relief efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
Rhea-AI Summary

Bausch Health Companies will participate in the 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. Key executives, including Joseph C. Papa (Chairman and CEO), Sam Eldessouky (SVP), and Arthur J. Shannon (SVP of Investor Relations), will present. Investors can access a live webcast and audio archive on the company’s Investor Relations page. Bausch Health focuses on pharmaceuticals, medical devices, and over-the-counter products, particularly in eye health, gastroenterology, and dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced on August 31, 2020, a plan to reduce its debt by $100 million through the redemption of senior notes. The company will redeem $100 million of its 5.875% Senior Notes due September 30, 2020, using cash generated from operations. An irrevocable notice of redemption will be issued to the record holders of these notes. Bausch Health aims to strengthen its financial position and continues to focus on advancing global health through its healthcare products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
Rhea-AI Summary

Bausch Health's subsidiary, Bausch + Lomb, has received approval from Australia's Therapeutic Goods Administration (TGA) for the BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses. This product is expected to be available to select practitioners in Australia by Q4 2020, with a nationwide launch planned for early 2021. This approval complements Bausch + Lomb's existing contact lens offerings and aligns with the company’s expansion strategy, which includes launches in Japan and the United States, as well as further expansions in Canada and Hong Kong.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
Rhea-AI Summary

Bausch + Lomb has launched the INFUSE™ silicone hydrogel daily disposable contact lens, designed to combat contact lens dryness affecting about half of U.S. lens wearers. This lens utilizes ProBalance Technology™ to maintain ocular surface homeostasis and retain 96% moisture for 16 hours. The advanced design aims to provide comfort without sacrificing vision correction. Bausch Health Companies Inc. (NYSE/TSX: BHC) emphasizes its commitment to innovative eye care solutions, reflecting the need for advanced materials in contact lens technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary

Bausch Health announced the approval of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses by Health Canada. These lenses incorporate Advanced MoistureSeal® Technology and ComfortFeel Technology, ensuring a high level of comfort and eye health for up to 16 hours. They will be available to select practitioners in Canada starting Q4 2020, with a full launch expected in early 2021. This innovation enhances Bausch + Lomb's existing product portfolio, aiming to improve patient experience in eye care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary

Bausch Health reported revenues of $1.664 billion for Q2 2020, a 23% decline from Q2 2019, largely due to the COVID-19 pandemic.

GAAP net loss was $326 million, compared to a $171 million loss in the same quarter last year.

The company has narrowed its full-year revenue guidance to $7.80 - $8.00 billion and Adjusted EBITDA to $3.15 - $3.30 billion.

Despite challenges, Bausch Health is focused on market share growth and launching new products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
Rhea-AI Summary

Bausch Health Companies Inc. (BHC) announced its plan to spin off its eye health business, creating an independent entity named Bausch + Lomb - NewCo. This strategic move aims to enhance focus on two distinct business segments: a dedicated eye health company and a diversified pharmaceutical firm specializing in gastroenterology, aesthetics/dermatology, and neurology. The spinoff is expected to improve financial transparency and unlock shareholder value. Bausch + Lomb - NewCo reported $3.7 billion in revenue for 2019, while BHC's revenue was $4.9 billion, with plans to report separate financials starting Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

Bausch Health Companies (BHC) last closed at $8.22.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately $3.1B.